Literature DB >> 1849983

Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity.

N K Blackburn1, T G Besselaar, B D Schoub, K F O'Connell.   

Abstract

Cytomegalovirus (CMV) is probably the most common agent of prenatal infection of the newborn, and one of 20 congenitally infected newborns shows serious symptoms. It was therefore considered important to be able to differentiate primary CMV from reactivation in pregnant females. A urea denaturation test was used to distinguish primary from secondary rubella infection in which the urea is included in the wash step of the standard IgG ELISA. This resulted in the removal of low-avidity antibodies, which are the antibodies produced early in infection. A group of CMV IgM-negative and -positive sera were tested, and all but one showed moderate to high avidity, with an avidity index reading of more than 30%. Among a group of babies 3-12 months of age, who were CMV IgM positive, 55% (16 of 29) showed low-avidity CMV antibodies. A small group of renal transplant patients and patients with clinically and laboratory-confirmed CMV gave more or less predicted avidity index results. It appears that, with the method used at this laboratory, the urea denaturation test can be applied to CMV to determine primary infection or reactivation in the majority of cases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849983     DOI: 10.1002/jmv.1890330103

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  24 in total

1.  Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects.

Authors:  T Lazzarotto; P Spezzacatena; P Pradelli; D A Abate; S Varani; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors:  Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Primary humoral antibody response to Coxiella burnetii, the causative agent of Q fever.

Authors:  D Guigno; B Coupland; E G Smith; I D Farrell; U Desselberger; E O Caul
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

4.  Introduction to Measurement of Avidity of Anti-Coxiella burnetii IgG in Diagnosis of Q Fever.

Authors:  Léa Luciani; Coralie L'Ollivier; Matthieu Million; Bernard Amphoux; Sophie Edouard; Didier Raoult
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

5.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Differentiation of primary from nonprimary genital herpes infections by a herpes simplex virus-specific immunoglobulin G avidity assay.

Authors:  M Hashido; S Inouye; T Kawana
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

7.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

8.  Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349-368 aa by anti-La/SSB autoantibodies from patients with systemic autoimmune diseases.

Authors:  A G Terzoglou; J G Routsias; S Avrameas; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

9.  Multicenter evaluation of a rapid and convenient method for determination of cytomegalovirus immunoglobulin G avidity.

Authors:  M Baccard-Longere; F Freymuth; D Cointe; J M Seigneurin; L Grangeot-Keros
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

10.  Clinical evaluation of a chemiluminescence immunoassay for determination of immunoglobulin g avidity to human cytomegalovirus.

Authors:  Maria Grazia Revello; Giovanna Gorini; Giuseppe Gerna
Journal:  Clin Diagn Lab Immunol       Date:  2004-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.